Donepezil for dementia with Lewy bodies: a randomized, placebo-controlled, confirmatory phase III trial

INTRODUCTION: The efficacy of a cholinesterase inhibitor, donepezil, in patients with dementia with Lewy bodies (DLB) was investigated to confirm the superiority over placebo in the 12-week, double-blind phase of this phase III study. METHODS: Patients with probable DLB (n = 142) were randomly assig...

Descripción completa

Detalles Bibliográficos
Autores principales: Ikeda, Manabu, Mori, Etsuro, Matsuo, Kazutaka, Nakagawa, Masaki, Kosaka, Kenji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4338565/
https://www.ncbi.nlm.nih.gov/pubmed/25713599
http://dx.doi.org/10.1186/s13195-014-0083-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4338565/
https://www.ncbi.nlm.nih.gov/pubmed/25713599
http://dx.doi.org/10.1186/s13195-014-0083-0

Ejemplares similares